2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)- acetamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5

A compound of formula (I):

• wherein:
• R1 represents a group selected from:
• a) phenyl ring unsubstituted or substituted by 1 or 2 groups selected from halogen, linear or branched C1-C3 haloalkyl, linear or branched C1-C3 alkyl, linear or branched C1-C3 alkoxy, cyano and hydroxy, and
• b) 5- or 6-membered heteroaryl ring unsubstituted or substituted by 1 or 2 groups selected from halogen, linear or branched C1-C3 haloalkyl, linear or branched C1-C3 alkyl, linear or branched C1-C3 alkoxy, cyano and hydroxy;
• R2 represents a group selected from:
• a) hydrogen, and
• b) linear or branched C1-C3 alkyl optionally substituted by 1, 2, or 3 halogen atoms;
• R3 represents a group selected from:
• a) hydrogen,
• b) linear or branched C1-C3 alkyl optionally substituted by 1, 2, or 3 halogen atoms, and
• c) halogen atom,
• R4 and R5 independently represent a group selected from:
• a) hydrogen,
• b) linear or branched C1-C3 alkyl optionally substituted by 1, 2, or 3 halogen atoms, and
• c) halogen;
• n is an integer from 0 to 3;
• R6 represents a group selected from the group consisting of:
• a) —N(R7)(R8), wherein R7 and R8 are independently selected from linear or branched C1-C6 alkyl or hydrogen, and
• b) saturated 4- to 10-membered, monocyclic or bicyclic, nitrogen-containing heterocyclyl optionally comprising another heteroatom selected from the group consisting of oxygen and nitrogen, said heterocyclyl being optionally substituted by C1-C3 alkyl;
• or a pharmaceutically acceptable salt thereof.